JAGX

Jaguar Health is a pre-scale specialty-pharma story (crofelemer/Mytesi for GI conditions) whose numbers describe a company fighting for survival, not one building value. Revenue has gone nowhere for four years — $12.0M (FY22), $9.76M (FY23), $11.7M (FY24), $11.5M (FY25, -1.5% YoY) — while losses widened: FY25 net loss was -$53.6M (worse by 39%), operating income -$45.9M, and operating margin an untenable -398.8%. R&D was pushed UP 50.9% to $25.0M into that shrinking cash position, which tells you management is spending toward pipeline hope, not disciplining the burn. The 10-K's own forward-looking language leans entirely on 'prospective products,' 'product approvals,' 'commercialization plans and timing' and 'likelihood of success' — i.e., the equity is a bet on binary clinical/commercial events, not on the current book.

The balance sheet is the disqualifier. Stockholders' equity is NEGATIVE -$18.7M (down 388% YoY) — the company is technically insolvent. Cash fell 87.9% to just $968K against operating cash burn of -$23.7M; at that rate the company has effectively no runway without immediate financing. Current liabilities of $40.7M (up 106%) dwarf current assets of $20.3M — a working-capital hole of ~$20M — and total liabilities of $57.0M exceed total assets of $38.3M. Accumulated deficit is -$400M. This is the textbook setup for a going-concern qualification.